세계의 임질 치료제 시장 보고서(2025년)

Gonorrhea Therapeutics Global Market Report 2025

US $ 4,490 ￦ 6,242,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,023,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,803,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

임질 치료제 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 5.2%로 성장할 전망이며, 24억 2,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 성병 이환율 증가, 맞춤형 의료에 대한 관심 증가, 항생제 내성 패턴 증가, 임질 유병률 증가, 효과적인 치료에 대한 수요 증가로 인한 것입니다. 주요 동향으로는 기술 개발, 고급 진단 테스트 개발, 새로운 치료제, 병용 요법, 신속한 의약품 승인에 대한 규제 당국의 지원 등이 있습니다.

성감염증(STI)의 이환율 증가는 앞으로 수년간 임질 치료제 시장의 성장을 이끌 것으로 예측됩니다. STI는 성적 접촉에 의해 감염되는 감염으로 박테리아, 바이러스 및 기생충에 의해 유발됩니다. STI 증가는 무방비적인 성행위, 인식 및 교육의 부족, 성적 파트너 증가, 콘돔 사용의 감소, 검사 및 치료의 불충분함과 지연 등의 요인에 기인하고 있습니다. 임질 치료제는 임균을 표적으로 한 STI 치료, 합병증 예방, 감염 감소에 중요한 역할을 합니다. 예를 들어 2024년 6월 네덜란드 정부 기관인 국립공중보건환경연구소는 SHC로 진단받은 임질 환자가 크게 증가했고 2022년 1만 600명에서 2023년 1만 3853명으로 증가했다고 보고했습니다. 이러한 STI의 유병률 증가는 임질 치료제 시장의 확대에 박차를 가하고 있습니다.

임질 치료제 시장의 주요 기업은 신속한 중합 효소 연쇄반응(PCR) 검사와 같은 혁신적인 솔루션 개발에 주력하고 있으며, 의료 현장에서 신속하고 정확하게 병원체를 검출하고 항생제 내성을 분석할 수 있도로고 하고 있습니다. 신속 PCR 검사는 특정 DNA 또는 RNA 서열을 증폭 및 검출하는 진단 도구이며, 병원체와 유전 물질의 신속한 동정을 가능하게 합니다. 예를 들면, 2024년 2월, 미국의 의료기술 기업인 Visby Medical, Inc.는 항균제 내성 검사를 포함한 임질 검사를 발표했습니다. 이 신속 진단 검사는 임질의 원인균인 임균의 존재를 확인하는 동시에 일부 임균이 내성을 획득하고 있는 항생물질인 시프로플록사신에 대한 감수성을 평가합니다. 이 검사는 휴대용이고 기구를 필요로 하지 않는 PCR 플랫폼의 일부이며 포인트 오브 케어에서 즉시 검사를 가능하게 합니다. 미국 비영리단체 CARB-X의 자금 제공을 받아 개발된 이 검사는 남성 클라미디아 트라코마티스와 트리코모나스 질염을 포함한 다른 성병 검출로도 확대될 예정입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

• 세계의 임질 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 임질 치료제 시장 : 성장률 분석
• 세계의 임질 치료제 시장 실적 : 규모 및 성장(2019-2024년)
• 세계의 임질 치료제 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
• 세계의 임질 치료제 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 임질 치료제 시장 : 치료 클래스별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 항생제
• 병용 요법
• 단제요법
• 세계의 임질 치료제 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 오랄
• 정맥내
• 근육내
• 세계의 임질 치료제 시장 : 연령층별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 소아과
• 성인용
• 고령자
• 세계의 임질 치료제 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 소매 약국
• 온라인 약국
• 세계의 임질 치료제 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 클리닉
• 홈케어
• 세계의 임질 치료제 시장 : 항생제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 베타 락탐
• 마크로라이드
• 플루오로퀴놀론
• 아미노글리코시드
• 세계의 임질 치료제 시장 : 병용 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 이중 항생제 요법
• 3제 병용 항생제 요법
• 세계의 임질 치료제 시장 : 단제 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 단회 항생제 치료
• 기타 단독 요법의 선택

제7장 지역별 및 국가별 분석

• 세계의 임질 치료제 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 임질 치료제 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

• 임질 치료제 시장 : 경쟁 구도
• 임질 치료제 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • F. Hoffmann-La Roche Ltd 개요, 제품 및 서비스, 전략 및 재무 분석
  • Thermo Fisher Scientific Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Abbott Laboratories 개요, 제품 및 서비스, 전략 및 재무 분석
  • GlaxoSmithKline plc 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Becton Dickinson and Company
• Hologic Inc.
• Aurobindo Pharma Limited
• Innoviva Inc.
• Debiopharm Group
• Achilles Vaccines Srl
• Melinta Therapeutics LLC
• VenatoRx Pharmaceuticals Inc.
• Evofem Biosciences Inc.
• Recce Pharmaceuticals Ltd.
• Therapyx Inc.
• Entasis Therapeutics Inc.
• Apotex Inc.
• Alopexx Pharmaceuticals LLC
• Summit Therapeutics Inc.

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

• 임질 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
• 임질 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
• 임질 치료제 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

AJY

영문 목차

영문목차

Gonorrhea therapeutics refer to treatments and medications used to manage and cure gonorrhea, a sexually transmitted infection (STI) caused by *Neisseria gonorrhoeae. These treatments primarily rely on antibiotics, often administered in combination to prevent resistance and ensure effective bacterial eradication.

The main classes of gonorrhea therapeutics include antibiotics, combination therapy, and monotherapy. Antibiotics are specifically designed to eliminate the bacteria responsible for gonorrhea, commonly including drugs such as azithromycin and ceftriaxone. These treatments are administered through oral, intravenous, and intramuscular routes and are tailored for different age groups, including pediatric, adult, and geriatric patients. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, while the primary end users comprise hospitals, clinics, and home care settings.

The gonorrhea therapeutics market research report is one of a series of new reports from The Business Research Company that provides gonorrhea therapeutics market statistics, including the gonorrhea therapeutics industry global market size, regional shares, competitors with the gonorrhea therapeutics market share, detailed gonorrhea therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the gonorrhea therapeutics industry. This gonorrhea therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gonorrhea therapeutics market size has grown strongly in recent years. It will grow from $1.88 billion in 2024 to $1.98 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth during the historic period can be credited to the rising resistance of Neisseria gonorrhoeae, the increasing prevalence of gonorrhea, the growing impact of antimicrobial resistance (AMR), heightened antibiotic resistance, and the expanding use of dual therapy treatments.

The gonorrhea therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.42 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be credited to the rising incidence of sexually transmitted infections, a growing focus on personalized medicine, increasing antibiotic resistance patterns, a higher prevalence of gonorrhea, and the growing demand for effective treatment. Key trends include technological advancements, the development of advanced diagnostic tests, new therapeutics, combination therapies, and regulatory support for expedited drug approvals.

The rising incidence of sexually transmitted infections (STIs) is expected to drive the growth of the gonorrhea therapeutics market in the coming years. STIs are infections transmitted through sexual contact and are caused by bacteria, viruses, or parasites. The increase in STIs is attributed to factors such as unprotected sex, lack of awareness or education, a higher number of sexual partners, reduced condom use, and inadequate or delayed testing and treatment. Gonorrhea therapeutics play a crucial role in treating STIs by targeting the Neisseria gonorrhoeae bacteria, preventing complications, and reducing transmission. For example, in June 2024, the National Institute for Public Health and the Environment, a Netherlands-based government agency, reported a significant rise in gonorrhea cases diagnosed at SHCs, increasing from 10,600 in 2022 to 13,853 in 2023, reflecting a 31% year-over-year growth. This growing prevalence of STIs is fueling the expansion of the gonorrhea therapeutics market.

Leading companies in the gonorrhea therapeutics market are focused on developing innovative solutions, such as rapid polymerase chain reaction (PCR) tests, to enable quick and accurate pathogen detection and antibiotic resistance analysis at the point of care. A rapid PCR test is a diagnostic tool that amplifies and detects specific DNA or RNA sequences, allowing for fast identification of pathogens or genetic material. For instance, in February 2024, Visby Medical, Inc., a US-based medical technology company, introduced a gonorrhea test that includes an antimicrobial resistance check. This rapid diagnostic test identifies the presence of Neisseria gonorrhoeae, the bacteria responsible for gonorrhea, while also assessing its susceptibility to ciprofloxacin, an antibiotic to which some gonorrhea strains have developed resistance. The test is part of a portable, instrument-free PCR platform that allows immediate testing at the point of care. Developed with funding from the US non-profit organization CARB-X, the company plans to expand the test to detect other sexually transmitted infections, including Chlamydia trachomatis and Trichomonas vaginalis, in men.

In November 2024, the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a US-based biopharmaceutical company, partnered with the Clinton Health Access Initiative (CHAI) to enhance antimicrobial resistance (AMR) response and address gonorrhea treatment challenges. This collaboration aims to assess clinical needs and overcome market barriers for gonorrhea diagnostics, prevention, and treatment in low- and middle-income countries, with a focus on drug-resistant Neisseria gonorrhoeae to improve patient care and expand access to effective AMR solutions. CHAI, a US-based health organization, works to improve access to gonorrhea therapeutics, including diagnostics, treatments, and preventive strategies.

Major players in the gonorrhea therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, GlaxoSmithKline plc, Becton Dickinson and Company, Hologic Inc., Aurobindo Pharma Limited, Innoviva Inc., Debiopharm Group, Achilles Vaccines S.r.l., Melinta Therapeutics LLC, VenatoRx Pharmaceuticals Inc., Evofem Biosciences Inc., Recce Pharmaceuticals Ltd., Therapyx Inc., Entasis Therapeutics Inc., Apotex Inc., Alopexx Pharmaceuticals LLC, and Summit Therapeutics Inc.

North America was the largest region in the gonorrhea therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gonorrhea therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gonorrhea therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gonorrhea therapeutics market consists of revenues earned by entities by providing services such as diagnostic testing services, sexual health and counseling services, telemedicine, and online consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The gonorrhea therapeutics market also includes sales of pediatric formulations, single-dose regimens, sulfonamides, and penicillin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gonorrhea Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gonorrhea therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gonorrhea therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gonorrhea therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutic Class: Antibiotics; Combination Therapy; Monotherapy
• 2) By Route Of Administration: Oral; Intravenous; Intramuscular
• 3) By Age Group: Pediatric; Adult; Geriatric
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End User: Hospitals; Clinics; Home Care
• Subsegments:
• 1) By Antibiotics: Beta-lactams; Macrolides; Fluoroquinolones; Aminoglycosides
• 2) By Combination Therapy: Dual Antibiotic Therapy; Triple Antibiotic Therapy
• 3) By Monotherapy: Single Antibiotic Treatment; Other Monotherapy Options
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Abbott Laboratories; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gonorrhea Therapeutics Market Characteristics

3. Gonorrhea Therapeutics Market Trends And Strategies

4. Gonorrhea Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Gonorrhea Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gonorrhea Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gonorrhea Therapeutics Market Growth Rate Analysis
• 5.4. Global Gonorrhea Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gonorrhea Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gonorrhea Therapeutics Total Addressable Market (TAM)

6. Gonorrhea Therapeutics Market Segmentation

• 6.1. Global Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Combination Therapy
• Monotherapy
• 6.2. Global Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Intramuscular
• 6.3. Global Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adult
• Geriatric
• 6.4. Global Gonorrhea Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Gonorrhea Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Care
• 6.6. Global Gonorrhea Therapeutics Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Beta-lactams
• Macrolides
• Fluoroquinolones
• Aminoglycosides
• 6.7. Global Gonorrhea Therapeutics Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dual Antibiotic Therapy
• Triple Antibiotic Therapy
• 6.8. Global Gonorrhea Therapeutics Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single Antibiotic Treatment
• Other Monotherapy Options

7. Gonorrhea Therapeutics Market Regional And Country Analysis

• 7.1. Global Gonorrhea Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gonorrhea Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gonorrhea Therapeutics Market

• 8.1. Asia-Pacific Gonorrhea Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gonorrhea Therapeutics Market

• 9.1. China Gonorrhea Therapeutics Market Overview
• 9.2. China Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gonorrhea Therapeutics Market

• 10.1. India Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gonorrhea Therapeutics Market

• 11.1. Japan Gonorrhea Therapeutics Market Overview
• 11.2. Japan Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gonorrhea Therapeutics Market

• 12.1. Australia Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gonorrhea Therapeutics Market

• 13.1. Indonesia Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gonorrhea Therapeutics Market

• 14.1. South Korea Gonorrhea Therapeutics Market Overview
• 14.2. South Korea Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gonorrhea Therapeutics Market

• 15.1. Western Europe Gonorrhea Therapeutics Market Overview
• 15.2. Western Europe Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gonorrhea Therapeutics Market

• 16.1. UK Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gonorrhea Therapeutics Market

• 17.1. Germany Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gonorrhea Therapeutics Market

• 18.1. France Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gonorrhea Therapeutics Market

• 19.1. Italy Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gonorrhea Therapeutics Market

• 20.1. Spain Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gonorrhea Therapeutics Market

• 21.1. Eastern Europe Gonorrhea Therapeutics Market Overview
• 21.2. Eastern Europe Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gonorrhea Therapeutics Market

• 22.1. Russia Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gonorrhea Therapeutics Market

• 23.1. North America Gonorrhea Therapeutics Market Overview
• 23.2. North America Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gonorrhea Therapeutics Market

• 24.1. USA Gonorrhea Therapeutics Market Overview
• 24.2. USA Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gonorrhea Therapeutics Market

• 25.1. Canada Gonorrhea Therapeutics Market Overview
• 25.2. Canada Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gonorrhea Therapeutics Market

• 26.1. South America Gonorrhea Therapeutics Market Overview
• 26.2. South America Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gonorrhea Therapeutics Market

• 27.1. Brazil Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gonorrhea Therapeutics Market

• 28.1. Middle East Gonorrhea Therapeutics Market Overview
• 28.2. Middle East Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gonorrhea Therapeutics Market

• 29.1. Africa Gonorrhea Therapeutics Market Overview
• 29.2. Africa Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gonorrhea Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Gonorrhea Therapeutics Market Competitive Landscape
• 30.2. Gonorrhea Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Gonorrhea Therapeutics Market Other Major And Innovative Companies

• 31.1. Becton Dickinson and Company
• 31.2. Hologic Inc.
• 31.3. Aurobindo Pharma Limited
• 31.4. Innoviva Inc.
• 31.5. Debiopharm Group
• 31.6. Achilles Vaccines S.r.l.
• 31.7. Melinta Therapeutics LLC
• 31.8. VenatoRx Pharmaceuticals Inc.
• 31.9. Evofem Biosciences Inc.
• 31.10. Recce Pharmaceuticals Ltd.
• 31.11. Therapyx Inc.
• 31.12. Entasis Therapeutics Inc.
• 31.13. Apotex Inc.
• 31.14. Alopexx Pharmaceuticals LLC
• 31.15. Summit Therapeutics Inc.

32. Global Gonorrhea Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gonorrhea Therapeutics Market

34. Recent Developments In The Gonorrhea Therapeutics Market

35. Gonorrhea Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Gonorrhea Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gonorrhea Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gonorrhea Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료